Clinical Trials Logo
  1. Home
  2. Other
  3. NCT05056779

Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis With Inadequate Response to or for Whom Cyclosporine A is Not Medically Advisable

Moderate-to-severe Atopic Dermatitis Clinical Trial

Official title:
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis With Inadequate Response to or for Whom Cyclosporine A is Not Medically Advisable

Clinical Trial Summary

The primary objective of this study is to investigate the efficacy of nemolizumab administered in combination with topical background therapy (topical corticosteroids [TCS] with or without topical calcineurin inhibitors [TCI]) in adult participants with moderate-to-severe atopic dermatitis (AD) who are not adequately controlled with or are not advised to use oral cyclosporine A (CsA) for medical reasons. The secondary objective is to investigate the safety of nemolizumab in adult participants with moderate-to-severe AD who are not adequately controlled with or are not advised to use oral CsA for medical reasons. The study will be carried out in up to 70 different locations across Europe.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05056779
Study type Interventional
Source Galderma R&D
Contact
Status Withdrawn
Phase Phase 3
Start date January 2023
Completion date July 2023
View Details
See also
  Status Clinical Trial Phase
Completed NCT03054428 - Efficacy and Safety of Dupilumab in Participants ≥12 to <18 Years of Age, With Moderate-to-severe Atopic Dermatitis Phase 3
Active, not recruiting NCT05899816 - A Study Assessing Rocatinlimab on Vaccine Antibody Response in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET - VOYAGER) Phase 3
Recruiting NCT04893707 - The Study of CM310 in Patients With Atopic Dermatitis Phase 2
Completed NCT03985943 - Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis Phase 3
Completed NCT03989349 - Efficacy & Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis Phase 3
Recruiting NCT04921345 - Pharmacokinetics, Safety and Efficacy of Nemolizumab in Participants With Moderate-to-Severe Atopic Dermatitis Phase 2
Completed NCT04893941 - Dose Escalation Trial of CM310 in Patients With Moderate-to-Severe Atopic Dermatitis (AD) Phase 1/Phase 2
Completed NCT04444752 - A Study to Assess the Efficacy and Safety of CBP-201 in Adult Subjects With Moderate to Severe Atopic Dermatitis Phase 2
Completed NCT05203380 - Neuropsychologic Assessments of Dupilumab-Treated Adolescent Participants With Moderate-to-Severe Atopic Dermatitis
Active, not recruiting NCT05590585 - Dupilumab in Adolescent and Adult Skin of Color Participants: Open-label Moderate-to-severe Eczema Trial Phase 4
Completed NCT04805411 - Subcutaneously CM310/Placebo in Patients With Moderate-to-Severe Atopic Dermatitis (AD) Phase 2
Recruiting NCT05186922 - The Study of CM326 in Patients With Moderate-to-severe Atopic Dermatitis Phase 1/Phase 2
Recruiting NCT03057860 - TREATgermany: German National Clinical Registry for Patients With Moderate-to-severe Atopic Dermatitis
Active, not recruiting NCT03989206 - Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis Phase 3
Recruiting NCT05671432 - The Study of CM326 in Moderate-to-severe Atopic Dermatitis Phase 2
Not yet recruiting NCT06158490 - A Study to Evaluate JYP0061 Tablets in Patients With Moderate-to-severe Atopic Dermatitis Phase 2
Terminated NCT05984784 - A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of IMG-007 in Adults With Atopic Dermatitis (AD) Phase 1/Phase 2
Completed NCT05017480 - A Study to Evaluate the Efficacy and Safety of CBP-201 in Moderate to Severe Atopic Dermatitis in China Phase 2